FDA-cleared profile

Seg Pro V3 (RT-300)

Ever Fortune.Ai, Co., Ltd. · Radiotherapy Planning Imaging · FDA-cleared (510(k))

Authorized purpose: Seg Pro V3 generates initial organ-at-risk contours on DICOM images for radiation-treatment planning by radiation oncologists, medical physicists, and dosimetrists; the contours require professional review and editing.

Clinical role
Radiotherapy contouring, treatment planning, adaptation, or treatment-session support under professional review.
Images and patients
Radiotherapy Planning Imaging · Head, neck, brain, thorax, abdomen, pelvis, and other labeled radiation-treatment regions
Key limitation
Keep in mind: Generated or modified contours and plans require qualified review, editing when needed, independent checks, and final approval before treatment.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Seg Pro V3 generates initial organ-at-risk contours on DICOM images for radiation-treatment planning by radiation oncologists, medical physicists, and dosimetrists; the contours require professional review and editing.
  • Which images or clinical context are in scope?Modality: Radiotherapy Planning Imaging Anatomy or clinical context: Head, neck, brain, thorax, abdomen, pelvis, and other labeled radiation-treatment regions Input: Supported CT or MR images, structures, prescriptions, plans, registrations, and treatment-session data.
  • Who uses it?Intended users: Qualified radiation oncologists, medical physicists, dosimetrists, and radiation therapists.
  • What does the software produce?Output: Contours, treatment plans, adapted plans, dose or evaluation results, or session information requiring review and approval.
  • What is its most important limitation?Key limitation: Generated or modified contours and plans require qualified review, editing when needed, independent checks, and final approval before treatment.

Clinical takeaway. Clinical role: Seg Pro V3 generates initial organ-at-risk contours on DICOM images for radiation-treatment planning by radiation oncologists, medical physicists, and dosimetrists; the contours require professional review and editing.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports a standalone performance evaluation of OAR contouring on 175 cases consecutively collected from TCIA datasets, independent of development data, with ground truth contours from three board-certified radiation oncologists. Overall mean DSC was 0.85; mean DSC values were 0.90, 0.86, and 0.73 for large-, medium-, and small-volume structures, and the primary endpoint was met. Clinical validation by independent clinical users was also reported. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Seg Pro V3 generates initial organ-at-risk contours on DICOM images for radiation-treatment planning by radiation oncologists, medical physicists, and dosimetrists; the contours require professional review and editing.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Radiotherapy contouring, treatment planning, adaptation, or treatment-session support under professional review.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Supported CT or MR images, structures, prescriptions, plans, registrations, and treatment-session data.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Contours, treatment plans, adapted plans, dose or evaluation results, or session information requiring review and approval.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Radiation-oncology departments using compatible planning, imaging, and treatment-delivery systems.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Qualified radiation oncologists, medical physicists, dosimetrists, and radiation therapists.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
Generated or modified contours and plans require qualified review, editing when needed, independent checks, and final approval before treatment.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports a standalone performance evaluation of OAR contouring on 175 cases consecutively collected from TCIA datasets, independent of development data, with ground truth contours from three board-certified radiation oncologists. Overall mean DSC was 0.85; mean DSC values were 0.90, 0.86, and 0.73 for large-, medium-, and small-volume structures, and the primary endpoint was met. Clinical validation by independent clinical users was also reported. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "In addition, a standalone performance evaluation was conducted to assess the Organ-at-Risk (OAR)contouringcapabilities" … "The dataset comprised 175 cases consecutively collected from the Cancer Imaging Archive (TCIA) datasets, all meeting the predefined inclusion criteria. All data used during the standalone performance evaluation were acquired independently from product development training and internal testing.". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports a standalone performance evaluation of OAR contouring on 175 cases consecutively collected from TCIA datasets, independent of development data, with ground truth contours from three board-certified radiation oncologists. Overall mean DSC was 0.85; mean DSC values were 0.90, 0.86, and 0.73 for large-, medium-, and small-volume structures, and the primary endpoint was met. Clinical validation by independent clinical users was also reported. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "In addition, a standalone performance evaluation was conducted to assess the Organ-at-Risk (OAR)contouringcapabilities" … "The dataset comprised 175 cases consecutively collected from the Cancer Imaging Archive (TCIA) datasets, all meeting the predefined inclusion criteria. All data used during the standalone performance evaluation were acquired independently from product development training and internal testing.". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Sensitivity is not a product-wide endpoint for this system or software function. Compare only an exact endpoint, threshold, population, version, and source if one is later verified.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Specificity is not a product-wide endpoint for this system or software function. Compare only an exact endpoint, threshold, population, version, and source if one is later verified.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K251306 FDA evidence package for Seg Pro V3 (RT-300)

  • DesignFDA software substantial-equivalence decision with contouring, DICOM RTSTRUCT, algorithm, usability, and workflow verification
  • PopulationAdult radiation-treatment planning cases using supported DICOM images and labeled organs at risk
  • Scopeexact submission
  • Tested versionSeg Pro V3
  • IndependenceSponsor or vendor study

K251306

Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K251306 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS radiation-oncology material. Evaluate net planning or delivery value within the radiotherapy service line.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance or approval.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Supported CT or MR images, structures, prescriptions, plans, registrations, and treatment-session data.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K251306: Seg Pro V3 (RT-300)

  2. Routing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The public exact-submission material does not establish a complete integration contract. Confirm DICOM, worklist, identity, interfaces, exports, routing, audit behavior, and downtime locally.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 ·

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The public exact-submission material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 ·

  4. Returned objects

    Source context, not route validation: Contours, treatment plans, adapted plans, dose or evaluation results, or session information requiring review and approval.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K251306: Seg Pro V3 (RT-300)

  5. Viewer/worklist/report

    Unresolved route: Contours, treatment plans, adapted plans, dose or evaluation results, or session information requiring review and approval.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K251306: Seg Pro V3 (RT-300)

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Security
Ever Fortune.AI's investor information-security policy page states an implemented information security management system covering confidentiality, integrity, and availability, with security training and measurement targets; the page states the company has completed ISO 27001 certification and holds ISO/IEC 27701 PII-processor certification after independent third-party audit. The company's certification-milestones page lists ISO/IEC 27001:2022, ISO 22301:2019, ISO/IEC 27018:2019, and ISO/IEC 27017:2015.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement; certificates were not read. Applicant name variants (including uppercase and punctuation variants of Ever Fortune.AI Co., Ltd.) are bridged via the vendor's EFAI product naming and the owning domain everfortuneai.com.tw. Exact-release scope is not established.

Training
Only qualified radiation oncologists, medical physicists, dosimetrists, and radiation therapists should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Generated or modified contours and plans require qualified review, editing when needed, independent checks, and final approval before treatment.
  • Product family
  • Checked 2026-09-04

Current vendor material is product-family context for K251306; confirm exact cleared version, enabled options, deployment, and local compatibility.

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K251306 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Exact public integration details remain incomplete; establish and test the supported input, output, identity, routing, archive, and downtime contract locally.

product family · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally. Current vendor material is product-family context; confirm exact release, enabled options, deployment, and local compatibility.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Generated or modified contours and plans require qualified review, editing when needed, independent checks, and final approval before treatment.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.

Lifecycle monitoring

Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Generated or modified contours and plans require qualified review, editing when needed, independent checks, and final approval before treatment.

product family · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. Current vendor material is product-family context; confirm exact release, enabled options, deployment, and local compatibility.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K251306
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiotherapy Planning Imaging
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Head, neck, brain, thorax, abdomen, pelvis, and other labeled radiation-treatment regions
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-01-28
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-20Last searched
27Fields reviewed
13Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision material, vendor product page, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, fda decision summary, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission

    The public exact-submission material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.

  • Integration: Not publicly available - checked 2026-09-04 - Exact FDA submission

    The public exact-submission material does not establish a complete integration contract. Confirm DICOM, worklist, identity, interfaces, exports, routing, audit behavior, and downtime locally.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

8 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K251306: Seg Pro V3 (RT-300)

    U.S. Food and Drug Administration - Published 2026-01-28 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  6. Radiation Oncology Model

    Centers for Medicare & Medicaid Services - Accessed 2026-09-02

    Scope: reimbursement, radiationTherapyPaymentContext

  7. Seg Pro family

    Ever Fortune - Accessed 2026-09-04

    Scope: productFamilyContext, workflowRole, implementationCapabilities

  8. Ever Fortune.AI: Information Security Policy (ISO 27001 / ISO 27701)

    Ever Fortune.AI - Accessed 2026-10-27

    Scope: security

Research history

  1. K251306 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253050

RadOncAI

Informai

An AI-guided planning tool that predicts radiation dose information for adult head-and-neck treatment planning.

Modality
Radiotherapy Planning Imaging
Anatomy
Head and neck
Decision
2026-06-18
FDA-cleared K252190

DeepBT Detector-Plus

Aitewan Biomedical Technology, Inc.

Authorized purpose: DeepBT Detector-Plus provides initial gross-tumor-volume contours on T1-weighted contrast-enhanced and optional T2-weighted MR images for radiation-treatment planning in adults with the labeled brain tumors.

Modality
Radiotherapy Planning Imaging
Anatomy
Brain tumors, including metastases, meningiomas, and acoustic neuromas
Decision
2026-04-10
FDA-cleared K252548

AI-Rad Companion Organs RT

Siemens Healthcare GmbH

Authorized purpose: AI-Rad Companion Organs RT VA70 automatically contours predefined structures, including known diagnosed brain metastases, on DICOM CT and MR images for radiation therapy planning; qualified users must review, edit and accept contours in suitable planning or contouring software, and the device is not intended for diagnosis.

Modality
Radiotherapy Planning Imaging
Anatomy
Head/neck, thorax, abdomen, pelvis; MR brain and male pelvis
Decision
2026-04-10
FDA-cleared K260509

AutoContour (RADAC V5)

Radformation, Inc.

Authorized purpose: AutoContour Model RADAC V5 assists radiation treatment planners with contouring and reviewing structures in medical images for radiation therapy treatment planning. It produces initial machine-learning contours for user review and modification; it does not independently approve a contour or treatment plan.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2026-03-19

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history